This company has been marked as potentially delisted and may not be actively trading. Jupiter Neurosciences (JUNS) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesTrendsBuy This Stock JUNS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Jupiter Neurosciences appoints new auditor amid transitionApril 23, 2025 | investing.comJupiter Neurosciences Highlights Upcoming Milestones in Shareholder LetterApril 8, 2025 | finance.yahoo.comJupiter Neurosciences faces NASDAQ delisting over share priceMarch 27, 2025 | investing.comAlliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVMarch 7, 2025 | markets.businessinsider.comJupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan ProductsMarch 4, 2025 | markets.businessinsider.comJupiter Neurosciences says volatility ‘appears to be driven by misconceptions’February 5, 2025 | markets.businessinsider.comJupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial MilestonesFebruary 4, 2025 | globenewswire.comJupiter Neurosciences partners with Catalent for Parkinson's trialFebruary 3, 2025 | msn.comJupiter Neurosciences announces JOTROL manufaturing agreement with CatalentFebruary 3, 2025 | markets.businessinsider.comJupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s TrialFebruary 3, 2025 | markets.businessinsider.comJupiter Neurosciences partners with Zina for Parkinson's trialJanuary 30, 2025 | msn.comJupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s TrialJanuary 30, 2025 | markets.businessinsider.comJupiter Neurosciences, Inc. Partners with Zina Biopharmaceuticals for Phase 2a Clinical Trial of JOTROL in Parkinson's DiseaseJanuary 30, 2025 | quiverquant.comJupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's TrialJanuary 30, 2025 | globenewswire.comJupiter Neurosciences, Inc. (JUNS)January 22, 2025 | finance.yahoo.comJupiter Neurosciences Inc JUNSJanuary 22, 2025 | morningstar.comJupiter Neurosciences announces focus on NLRP3 pathway in JOTROL trialsJanuary 14, 2025 | markets.businessinsider.comJupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ TrialsJanuary 13, 2025 | markets.businessinsider.comJupiter Neurosciences Inc trading resumesJanuary 4, 2025 | markets.businessinsider.comJupiter Neurosciences Inc trading halted, volatility trading pauseJanuary 4, 2025 | markets.businessinsider.comJupiter Neurosciences, Inc. Closes Initial Public Offering Raising $11 Million for JOTROL™ Development and Expansion EffortsDecember 4, 2024 | quiverquant.comJupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public OfferingDecember 4, 2024 | globenewswire.comJupiter Neurosciences, Inc. Prices Initial Public Offering at $4.00 per ShareDecember 2, 2024 | quiverquant.comJupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and ...December 2, 2024 | gurufocus.comFact check: False claim 'Star of Bethlehem' will shine for first time since 1226 on Dec. 21December 21, 2023 | usatoday.comWhy We Lie, And The Neuroscience Behind ItOctober 8, 2023 | forbes.comHow do you attack brain cancer? A world-class lab in Jupiter is trying something innovative.July 29, 2023 | msn.comNeuroscience Explains Why You Need To Write Down Your Goals If You Actually Want To Achieve ThemApril 23, 2023 | forbes.comJupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL™ in Parkinson's DiseaseMarch 1, 2023 | morningstar.comWatch Venus and Jupiter Close In on a Glorious ConjunctionFebruary 23, 2023 | cnet.comFAU STILES-NICHOLSON BRAIN INSTITUTE OPENS HERALDING A NEW ERA IN NEUROSCIENCE AND EDUCATIONJanuary 22, 2023 | finance.yahoo.comFAU opens $45M neuroscience building (Photos)January 22, 2023 | bizjournals.comResveratrol drug developer Jupiter Neuroscience sets price for proposed $15M IPODecember 5, 2022 | seekingalpha.comJupiter Neurosciences Inc (JUNS)September 25, 2022 | investing.comDaily Markets: Markets Wait for Fed's Rate Decision and Powell's SpeechSeptember 21, 2022 | nasdaq.comStocks To Watch: Investors Eye Fed Meeting, Nvidia's Tech Event And Porsche IPOSeptember 19, 2022 | seekingalpha.comDaily Markets: No Short Path to Bringing Inflation Down to 2% TargetSeptember 14, 2022 | nasdaq.comJupiter Neurosciences, Inc IPOs Tomorrow, Here's What You Need To KnowSeptember 13, 2022 | msn.comDaily Markets: Inflation Report Sure to Move Markets, But Not FedSeptember 13, 2022 | nasdaq.comDaily Markets: Waiting for Inflation Data, the Dollar Trades OffSeptember 12, 2022 | nasdaq.comJupiter Neurosciences, Inc To Start Trading TomorrowSeptember 6, 2022 | benzinga.com Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Email Address JUNS Media Mentions By Week JUNS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JUNS News Sentiment▼0.940.87▲Average Medical News Sentiment JUNS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JUNS Articles This Week▼21▲JUNS Articles Average Week Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GALT News Today IMAB News Today ANIX News Today CLYM News Today IOBT News Today PLRX News Today PYXS News Today CPIX News Today EPIX News Today IGMS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JUNS) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s Next Move Could Shock Wall StreetIn just a few weeks, a move decades in the making could be revealed — and when it is, it could ignite the next...Golden Portfolio | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JUNS Stock Free JUNS Stock Alerts